Price movement over the last 24 hours
ADMA Biologics Inc vs Vanguard Real Estate Index Fund ETF — how do they compare? ADMA Biologics Inc trades at $9.24 (market cap $2.13B), while Vanguard Real Estate Index Fund ETF trades at $97.29. The key difference: Vanguard Real Estate Index Fund ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | VNQ | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | — |
52-Week High | $20.38 | $98.66 |
52-Week Low | $7.60 | $87.00 |
Enterprise Value | $2.20B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
VNQ (Vanguard Real Estate ETF) trades at $97.24, down 0.8% on the day, with technical indicators showing a bullish trend supported by moving averages. The ETF's recent performance reflects renewed investor interest in REITs amid shifting rate expectations, with June 2026 marking the sector's best monthly performance in years according to market data. Dividend payments remain a key attraction, with the next distribution scheduled for June 2026.
The outlook for VNQ appears cautiously optimistic as REIT fundamentals show resilience despite elevated interest rates. Investment opportunity lies in potential rate stabilization and sector rotation, while risks include persistent inflation pressure and Treasury yield volatility. Analyst sentiment is mixed, with some highlighting discounted valuations while others caution about sector-specific challenges.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →